ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vepdegestrant

Also written as “ARV-471”, “Vepdegestrant” and “[phenyl-14C]ARV-471”.

Its studies are mostly in Breast Neoplasms, led by 3 companies.

Drug pageVepdegestrant: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 16, 202220 company-led studies, 6 open or runningNext primary completion: Dec 4, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only176 open or runningphase 3since Nov 16, 2022Jul 14, 2022Dec 4, 2026phase 1 · NCT07231991
Arvinas Estrogen Receptor20 open or runningphase 2since Aug 27, 2019Aug 27, 2019none ahead
Arvinasits history only10 open or runningphase 2since Sep 7, 2022Sep 7, 2022none ahead

Also a collaborator on its studies: Carrick Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Arvinas Estrogen Receptor only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 27, 2019First study: phase 2 study in Breast NeoplasmsFirst studyNCT04072952 · 219 enrolled · United States
  2. Jul 21, 2022Named vepdegestrantINNProposed as its International Nonproprietary Name in WHO's List 127 · before, ARV-471
  3. Aug 9, 2022Phase 1 study in Breast NeoplasmsNCT05501769 · 32 enrolled · United States, Spain

TargetBeta

ESR1 →read by rule
“An orally available hetero-bifunctional molecule and selective estrogen receptor (ER) alpha-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, ”NCIt, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 2 Arvinas Estrogen Receptor leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05501769Breast Neoplasms · United States, Spain1CompletedJul 3, 202432
NCT04072952Breast Neoplasms · United States2CompletedSep 13, 2024219

How it is read

Names in the registry

  • “ARV-471”, 7 entries
  • “vepdegestrant”, 6 entries
  • “Vepdegestrant”, 4 entries
  • “[phenyl-14C]ARV-471”, 1 entry
  • “[oxoisoindolin-14C]ARV-471”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.